02-06-2025
Sanofi buying Blueprint Medicines for up to $9.5 billion
Sanofi agreed to acquire Blueprint Medicines, a Cambridge, Mass.-based biotech focused on rare immunology diseases, for $9.1 billion in cash and up to $400 million in earnouts.
Why it matters: This is Sanofi's third big buy in 2025, following Dren Bo and Vigil Neuroscience, as it tries to build up a portfolio that's become too reliant on its Dupixent anti-inflammatory drug.
The situation that's been exacerbated by some recent clinical setbacks and the April sale of a control stake in its consumer health unit to Clayton Dubilier & Rice for €10 billion.
By the numbers: Blueprint stockholders are slated to receive $129 per share at closing, representing a 23.3% premium over Friday's closing price.
They'd also get contingent value rights that could include up to $6 in milestone payments.
